Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

Published:2019-04-24 Issue:6 Volume:8 Page:2858-2866
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Zhuang Xibin¹,Zhao Chao²^ORCID,Li Jiayu³,Su Chunxia³,Chen Xiaoxia³,Ren Shengxiang³^ORCID,Li Xuefei²,Zhou Caicun²³

Affiliation:

1. Department of Respiratory Medicine Quanzhou First Hospital Quanzhou China

2. Department of Lung Cancer and Immunology Shanghai Pulmonary Hospital, Tongji University Shanghai China

3. Department of Medical Oncology Shanghai Pulmonary Hospital, Tongji University Shanghai China

Funder

Shanghai Hospital Development Center

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2183

Reference41 articles.

1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

3. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

4. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

5. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report;World Journal of Clinical Oncology;2024-07-24

2. The Interplay Between Cardiovascular Disease and Lung Cancer;Cureus;2024-06-23

3. The rapidly changing field of predictive biomarkers of non-small cell lung cancer;Pathology and Oncology Research;2024-06-17

4. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

5. Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features;The Journal of Thoracic and Cardiovascular Surgery;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3